|
|
|
| Effect of tyrosine kinase inhibitor combined with whole brain radiotherapy time on brain metastasis of lung adenocarcinoma with EGFR gene mutation |
| YAN Yafei GE Wei |
| Center of Oncology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
Abstract Objective To investigate the effect of tyrosine kinase inhibitors (TKI) combined with whole blood recalcification time (WBRT) on brain metastasis of lung adenocarcinoma with mutant epidermal growth factor receptor (EGFR) gene. Methods From June 2014 to June 2017, 42 patients with brain metastasis of EGFR-mutated lung adenocarcinoma diagnosed by pathology in Renmin Hospital of Wuhan University were collected, including 22 patients treated with EGFR-TKI combined with WBRT (combination therapy group) and 20 patients treated with EGFR-TKI alone (pure treatment group). Overall survival (OS) was the main observation index, the secondary observational indicator was intracranial progression (iPFS). Results There were statistically significant differences between the two groups in the presence or absence of intracranial symptoms and the diameter of intracranial metastases (P ＜ 0.05). There were no statistically significant differences in the number of intracranial metastases, gender, age, smoking history, ECOG score, presence or absence of extracranial metastases, CEA, CA125, CYFRA, SCC, and NSE (all P ＞ 0.05). IPFS in the combined treatment group was longer than that in the pure treatment group (P ＜ 0.05). Combined treatment may prolong OS in patients, but the difference between the two groups is not statistically significant (P ＞ 0.05). Conclusion No significant survival benefit was observed in patients with EGFR mutant lung adenocarcinoma with brain metastasis treated with WBRT, which should be validated by prospective randomized controlled studies.
|
|
|
|
|
|
[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：Sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：E359-E386.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2017 [J]. CA：A Cancer Journal for Clinicians，2017，67（1）：7-30.
[3] Goncalves PH，Peterson S，Vigneau FD，et al. Risk of Brain Metastases in Patients with Non-metastatic Lung Cancer：Analysis of the Metropolitan Detroit Surveillance，Epidemiology，and End Results （SEER） Data [J]. Cancer-Am Cancer Soc，2016，122（12）：1921-1927.
[4] 石远凯，孙燕，于金明，等.中国肺癌脑转移诊治专家共识（2017年版）[J].中国肺癌杂志，2017，20（1）：1-13.
[5] Kris MG，Johnson BE，Berry LD，et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs [J]. JAMA，2014，311（19）：1998-2006.
[6] Soh J，Toyooka S，Matsuo K，et al. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma [J]. Oncol Lett，2015，10（3）：1775-1782.
[7] Ahluwalia MS，Becker K，Levy BP. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer [J]. The Oncologist，2018，23（10）：1199-1209.
[8] Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease [J]. Target Oncol，2018， 13（3）：269-285.
[9] Wu YL，Zhou C，Cheng Y，et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases：a phase Ⅱ study （CTONG-0803） [J]. Ann Oncol，2013，24（4）：993-999.
[10] Iuchi T，Shingyoji M，Sakaida T，et al. Phase Ⅱ trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma [J]. Lung Cancer，2013，82（2）：282-287.
[11] Porta R，Sánchez-Torres JM，Paz-Ares L，et al. Brain metastases from lung cancer responding to erlotinib：the importance of EGFR mutation [J]. Eur Respir J，2011，37（3）：624-631.
[12] Welsh JW，Komaki R，Amini A，et al. Phase Ⅱ Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer [J]. J Clin Oncol，2013，31（7）：895-902.
[13] Chen Y，Yang J，Li X，et al. First‐line epidermal growth factor receptor （EGFR）–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma [J]. Cancer Sci，2016，107（12）：1800-1805.
[14] Zeng YD，Zhang L，Liao H，et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer：a retrospective study [J]. Asian Pac J Cancer Prev，2012，13（3）：909-914.
[15] Zhu Q，Sun Y，Cui Y，et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor （EGFR） mutant non small cell lung cancer （NSCLC）[J]. Oncotarget，2017，8（8）：13304-13311.
[16] Jiang T，Su C，Li X，et al. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases [J]. J Thorac Oncol，2016，11（10）：1718-1728.
[17] Byeon S，Ham JS，Sun J，et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis [J]. Med Oncol，2016，33（8）：97.
[18] 王洋，方健，聂鋆，等.非小细胞肺癌脑转移放疗时机的选择及疗效预后分析[J].中国肺癌杂志，2016，19（8）：508-514.
[19] Magnuson WJ，Lester-Coll NH，Wu AJ，et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na?觙ve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer：A Retrospective Multi-Institutional Analysis [J]. J Clin Oncol，2017，35（10）：1070-1077.
[20] Yomo S，Oda K. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma：A retrospective analysis of 133 consecutive patients [J]. Lung Cancer，2018，119：120-126. |
|
|
|
